SNX-2112
- Generic Name
- SNX-2112
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27F3N4O3
- CAS Number
- 908112-43-6
- Unique Ingredient Identifier
- 10C9P3FFOW
- Background
SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.
- Indication
Used for the treatment of schizophrenia .
- Associated Conditions
- -
- Associated Therapies
- -
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT03784222
- Locations
- 🇨🇳
Peking University Sixth Hospital, Beijing, Beijing, China
🇨🇳Shanghai Mental Health Center, Shanghai, Shanghai, China
🇨🇳Beijing Huilongguan Hospital, Beijing, Beijing, China
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd.
- Target Recruit Count
- 267
- Registration Number
- NCT01516424
- Locations
- 🇨🇳
Peking University Sixth Hospital, Beijing, Beijing, China
🇨🇳Henan Provincial Mental Hospital, Xinxiang, Henan, China
🇨🇳Hunan Province Brain Hospital, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath